IL258772B - Jak kinase inhibitory compounds for the treatment of respiratory disease - Google Patents
Jak kinase inhibitory compounds for the treatment of respiratory diseaseInfo
- Publication number
- IL258772B IL258772B IL258772A IL25877218A IL258772B IL 258772 B IL258772 B IL 258772B IL 258772 A IL258772 A IL 258772A IL 25877218 A IL25877218 A IL 25877218A IL 258772 B IL258772 B IL 258772B
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- kinase inhibitor
- respiratory disease
- inhibitor compounds
- jak kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250113P | 2015-11-03 | 2015-11-03 | |
| PCT/US2016/059999 WO2017079205A1 (en) | 2015-11-03 | 2016-11-02 | Jak kinase inhibitor compounds for treatment of respiratory disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL258772A IL258772A (en) | 2018-06-28 |
| IL258772B true IL258772B (en) | 2021-01-31 |
Family
ID=57442794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL258772A IL258772B (en) | 2015-11-03 | 2018-04-17 | Jak kinase inhibitory compounds for the treatment of respiratory disease |
Country Status (22)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3712152T3 (da) | 2015-11-03 | 2021-03-22 | Topivert Pharma Ltd | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer |
| PL3371185T3 (pl) | 2015-11-03 | 2021-04-06 | Topivert Pharma Limited | Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych |
| KR20180073687A (ko) | 2015-11-03 | 2018-07-02 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물 |
| JP6974487B2 (ja) | 2017-03-09 | 2021-12-01 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ４員ヘテロ環式アミドを含むｊａｋ阻害剤 |
| CN110573157B (zh) * | 2017-05-01 | 2023-04-04 | 施万生物制药研发Ip有限责任公司 | 使用jak抑制剂化合物的治疗方法 |
| AU2018261591B2 (en) | 2017-05-01 | 2021-09-02 | Theravance Biopharma R&D Ip, Llc | Crystalline forms of a JAK inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| WO2019104225A1 (en) | 2017-11-22 | 2019-05-31 | Dauntless 2, Inc. | Therapeutic compound formulations |
| EP3810094A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| SG11202101785UA (en) * | 2018-09-04 | 2021-03-30 | Theravance Biopharma R&D Ip Llc | Process for preparing jak inhibitors and intermediates thereof |
| FI3837258T3 (fi) | 2018-09-04 | 2024-05-27 | Theravance Biopharma R&D Ip Llc | Dimetyyliaminoatsetidiiniamideja jak-estäjinä |
| KR20210056380A (ko) | 2018-09-04 | 2021-05-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제로서 5원 내지 7원 헤테로사이클릭 아마이드 |
| MX2021004582A (es) * | 2018-10-29 | 2021-06-15 | Theravance Biopharma R&D Ip Llc | Compuesto 2-azabiciclo hexano inhibidor de jak. |
| CN113316577A (zh) | 2018-11-19 | 2021-08-27 | 纽约大学 | 作为治疗剂的GLi1抑制剂 |
| JP7514025B2 (ja) * | 2019-02-25 | 2024-07-10 | ホーナン メディノ ファーマシューティカル テクノロジー カンパニー リミテッド | Ｊａｋ阻害剤化合物及びその使用 |
| CN114075200A (zh) * | 2020-08-14 | 2022-02-22 | 河南迈英诺医药科技有限公司 | 用于治疗重症肺炎的jak抑制剂化合物 |
| KR20210137087A (ko) | 2019-03-05 | 2021-11-17 | 인사이트 코포레이션 | 만성 폐 동종이식 기능장애의 치료를 위한 jak1 경로 억제제 |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021136345A1 (zh) * | 2019-12-30 | 2021-07-08 | 路良 | Jak抑制剂化合物及其用途 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| WO2022178215A1 (en) | 2021-02-19 | 2022-08-25 | Theravance Biopharma R&D Ip, Llc | Amino amide tetrahydro imidazo pyridines as jak inhibitors |
| CN117083273A (zh) | 2021-03-26 | 2023-11-17 | 施万生物制药研发Ip有限责任公司 | Jak抑制剂化合物的二盐酸盐的晶型 |
| TW202317550A (zh) * | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| CN114181055A (zh) * | 2021-12-21 | 2022-03-15 | 苏州楚凯药业有限公司 | 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法 |
| JP2025515078A (ja) | 2022-05-05 | 2025-05-13 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | 噴霧経口吸入による送達のためのネズルシチニブ |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| CA2532800C (en) | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| DK2089369T3 (da) | 2006-10-19 | 2011-05-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| JP5512665B2 (ja) | 2008-06-20 | 2014-06-04 | ジェネンテック， インコーポレイテッド | トリアゾロピリジンｊａｋ阻害剤化合物と方法 |
| US20110184013A1 (en) | 2008-10-01 | 2011-07-28 | Shelley Allen | Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| JP5651681B2 (ja) | 2009-04-03 | 2015-01-14 | 大日本住友製薬株式会社 | 代謝型グルタミン酸受容体５介在障害の治療のための化合物、およびその使用方法 |
| EP2459195A1 (en) | 2009-07-28 | 2012-06-06 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| ES2652287T3 (es) | 2009-12-21 | 2018-02-01 | Samumed, Llc | 1H-pirazol [3,4-b] piridinas y usos terapéuticos de las mismas |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| CN103476770B (zh) | 2010-11-25 | 2017-02-15 | 拉蒂欧制药有限责任公司 | 阿法替尼盐和多晶型物 |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| TW201513861A (zh) * | 2013-01-17 | 2015-04-16 | Galapagos Nv | 用於治療退化性及發炎疾病之新穎化合物 |
| MD4649C1 (ro) | 2013-12-05 | 2020-04-30 | Pfizer Inc. | Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide |
| ES2737696T3 (es) * | 2014-05-14 | 2020-01-15 | Pfizer | Pirazolopiridinas y pirazolopirimidinas |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| DK3712152T3 (da) | 2015-11-03 | 2021-03-22 | Topivert Pharma Ltd | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer |
| PL3371185T3 (pl) | 2015-11-03 | 2021-04-06 | Topivert Pharma Limited | Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych |
| KR20180073687A (ko) | 2015-11-03 | 2018-07-02 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물 |
| JP6974487B2 (ja) | 2017-03-09 | 2021-12-01 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ４員ヘテロ環式アミドを含むｊａｋ阻害剤 |
| CN110573157B (zh) | 2017-05-01 | 2023-04-04 | 施万生物制药研发Ip有限责任公司 | 使用jak抑制剂化合物的治疗方法 |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| AU2018261591B2 (en) | 2017-05-01 | 2021-09-02 | Theravance Biopharma R&D Ip, Llc | Crystalline forms of a JAK inhibitor compound |
| SG11202101785UA (en) | 2018-09-04 | 2021-03-30 | Theravance Biopharma R&D Ip Llc | Process for preparing jak inhibitors and intermediates thereof |
| FI3837258T3 (fi) | 2018-09-04 | 2024-05-27 | Theravance Biopharma R&D Ip Llc | Dimetyyliaminoatsetidiiniamideja jak-estäjinä |
| KR20210056380A (ko) | 2018-09-04 | 2021-05-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제로서 5원 내지 7원 헤테로사이클릭 아마이드 |
| MX2021004582A (es) | 2018-10-29 | 2021-06-15 | Theravance Biopharma R&D Ip Llc | Compuesto 2-azabiciclo hexano inhibidor de jak. |
| CN117083273A (zh) | 2021-03-26 | 2023-11-17 | 施万生物制药研发Ip有限责任公司 | Jak抑制剂化合物的二盐酸盐的晶型 |
-
2016
- 2016-11-02 KR KR1020187015680A patent/KR20180073687A/ko not_active Withdrawn
- 2016-11-02 TW TW105135436A patent/TWI710560B/zh not_active IP Right Cessation
- 2016-11-02 MY MYPI2018701385A patent/MY195427A/en unknown
- 2016-11-02 HK HK18111992.5A patent/HK1252685A1/zh unknown
- 2016-11-02 EP EP16804947.6A patent/EP3371186A1/en not_active Withdrawn
- 2016-11-02 AU AU2016350816A patent/AU2016350816B2/en not_active Ceased
- 2016-11-02 WO PCT/US2016/059999 patent/WO2017079205A1/en not_active Ceased
- 2016-11-02 CA CA3001542A patent/CA3001542C/en active Active
- 2016-11-02 MX MX2018005446A patent/MX374605B/es active IP Right Grant
- 2016-11-02 CN CN201680063886.1A patent/CN108349972B/zh not_active Expired - Fee Related
- 2016-11-02 BR BR112018008966-4A patent/BR112018008966B1/pt not_active IP Right Cessation
- 2016-11-02 UA UAA201806062A patent/UA123633C2/uk unknown
- 2016-11-02 US US15/341,226 patent/US10100049B2/en active Active
- 2016-11-02 JP JP2018522556A patent/JP6800969B2/ja not_active Expired - Fee Related
- 2016-11-02 EA EA201891091A patent/EA034914B1/ru unknown
- 2016-11-02 NZ NZ741737A patent/NZ741737A/en unknown
- 2016-11-02 PH PH1/2018/500828A patent/PH12018500828B1/en unknown
-
2018
- 2018-04-16 ZA ZA2018/02496A patent/ZA201802496B/en unknown
- 2018-04-17 IL IL258772A patent/IL258772B/en active IP Right Grant
- 2018-04-30 CL CL2018001145A patent/CL2018001145A1/es unknown
- 2018-04-30 SA SA518391470A patent/SA518391470B1/ar unknown
- 2018-05-29 CO CONC2018/0005640A patent/CO2018005640A2/es unknown
- 2018-07-18 US US16/038,424 patent/US10183942B2/en active Active
- 2018-12-10 US US16/215,194 patent/US10526330B2/en active Active
-
2019
- 2019-11-20 US US16/689,706 patent/US10913740B2/en not_active Expired - Fee Related
-
2021
- 2021-01-05 US US17/248,015 patent/US11299492B2/en active Active
-
2022
- 2022-03-07 US US17/688,001 patent/US11718616B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258772B (en) | Jak kinase inhibitory compounds for the treatment of respiratory disease | |
| IL253945A0 (en) | kdm1a inhibitors to treat the disease | |
| IL253062B (en) | Pyrazine compounds for the treatment of infectious diseases | |
| PT3212233T (pt) | Terapia combinada para o tratamento de doenças | |
| SMT201900172T1 (it) | Ammino triazoli sostituiti utili come inibitori della chitinasi umana | |
| HUE071008T2 (hu) | Pridopidin alkalmazása mûködési hanyatlás kezelésére | |
| IL285077A (en) | Compounds for the treatment of cancer | |
| EP4591936A3 (en) | Treatment of respiratory diseases | |
| IL254266A0 (en) | Glucosylceramide synthase inhibitors for the treatment of diseases | |
| IL257355B (en) | Selection of patients for combined treatment | |
| IL258593B (en) | Compounds for the treatment of subculture disorders | |
| IL253011B (en) | A novel inhibitory protein of pi3k gamma for the treatment of diseases in the respiratory system | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| GB201408387D0 (en) | Treatment of respiratory disorders | |
| HUE070257T2 (hu) | Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére | |
| ES3049333T3 (en) | Compounds for the treatment of respiratory diseases | |
| SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
| GB201714772D0 (en) | Dosage forms of therapeutic compounds | |
| GB201621398D0 (en) | Treatment of emt-associated disease | |
| GB201512635D0 (en) | Uses of therapeutic compounds | |
| GB201504413D0 (en) | Treatment of disease | |
| PL3331517T3 (pl) | Zastosowanie hydroksymocznika w celu zapobiegania brakowi perfuzji w siatkówce | |
| AU2015901032A0 (en) | Treatment of respiratory diseases | |
| GB201507937D0 (en) | Compounds for treatment of pancreatic cancer | |
| GB201406225D0 (en) | Treatment for respiratory disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |